Controlled human infection with Mycobacterium tuberculosis: practical considerations for clinical trials.

Saved in:
Bibliographic Details
Title: Controlled human infection with Mycobacterium tuberculosis: practical considerations for clinical trials.
Authors: Seshadri C; Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA; Seattle Tuberculosis Research Advancement Center, Seattle, WA, USA. Electronic address: seshadri@uw.edu., Flynn JL; Department of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, PA, USA., Maiello P; Department of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, PA, USA., Schnappinger D; Department of Microbiology and Immunology, Weill Cornell Medical College, New York, NY, USA., Wilkinson RJ; Wellcome Discovery Research Platform in Infection, Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, and Department of Medicine, University of Cape Town, South Africa; Department of Infectious Diseases, Imperial College London, London, UK; Francis Crick Institute, London, UK., Gordon SB; Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK; Malawi-Liverpool-Wellcome Research Programme, Kamuzu University of Health Sciences, Blantyre, Malawi; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK., Mwandumba HC; Malawi-Liverpool-Wellcome Research Programme, Kamuzu University of Health Sciences, Blantyre, Malawi; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK., Jambo KC; Malawi-Liverpool-Wellcome Research Programme, Kamuzu University of Health Sciences, Blantyre, Malawi; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK., Hoft DF; Division of Infectious Diseases, Allergy & Immunology, Center for Vaccine Development, and Department of Molecular Microbiology & Immunology, Saint Louis University School of Medicine, St. Louis, MO, USA., Rubin EJ; Department of Immunology and Infectious Diseases, Harvard TH Chan School of Public Health, Boston, MA, USA., Jamrozik E; Department of Infectious Diseases, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia; Ethox and Pandemic Sciences Institute, University of Oxford, Oxford, UK., Fortune SM; Department of Immunology and Infectious Diseases, Harvard TH Chan School of Public Health, Boston, MA, USA., Kublin JG; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Source: The Lancet. Microbe [Lancet Microbe] 2026 Mar; Vol. 7 (3), pp. 101278. Date of Electronic Publication: 2026 Jan 23.
Publication Type: Journal Article; Review
Journal Info: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101769019 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-5247 (Electronic) Linking ISSN: 26665247 NLM ISO Abbreviation: Lancet Microbe Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2666-5247
DOI:10.1016/j.lanmic.2025.101278